Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis.
about
Novel pandemic influenza A (H1N1) and community-associated methicillin-resistant Staphylococcus aureus pneumonia.Teicoplanin as an effective alternative to vancomycin for treatment of MRSA infection in Chinese population: a meta-analysis of randomized controlled trials.The study of vancomycin use and its adverse reactions associated to patients of a Brazilian university hospital.High risk of cross-reactivity between vancomycin and sequential teicoplanin therapy.Safety profiles of old and new antimicrobials for the treatment of MRSA infections.Teicoplanin dosing strategy for treatment of Staphylococcus aureus in Korean patients with neutropenic feverEvidence-based guidelines for empirical therapy of neutropenic fever in Korea.Prophylaxis with teicoplanin and cefuroxime reduces the rate of prosthetic joint infection after primary arthroplastyProposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltrationPredictors of mortality in Staphylococcus aureus BacteremiaTeicoplanin-based antimicrobial therapy in Staphylococcus aureus bone and joint infection: tolerance, efficacy and experience with subcutaneous administration.Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease.Comparison of Borate Bioactive Glass and Calcium Sulfate as Implants for the Local Delivery of Teicoplanin in the Treatment of Methicillin-Resistant Staphylococcus aureus-Induced Osteomyelitis in a Rabbit ModelOptimizing Polymyxin Combinations Against Resistant Gram-Negative BacteriaFatal persistent methicillin-resistant Staphylococcus aureus bacteremia and vascular graft infections complicated with the formation of multiple abscesses despite aggressive medical therapy.Tolerability and Plasma Drug Level Monitoring of Prolonged Subcutaneous Teicoplanin Treatment for Bone and Joint Infections.Multicenter prospective observational study of the comparative efficacy and safety of vancomycin versus teicoplanin in patients with health care-associated methicillin-resistant Staphylococcus aureus bacteremia.Is therapeutic drug monitoring of teicoplanin useful?Therapeutic drug concentrations of teicoplanin in clinical settings.Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy.Current trends in the management of cardiac implantable electronic device (CIED) infections.Antimicrobial resistance in internal medicine wards.The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties.Current pharmacotherapy options for osteomyelitis: convergences, divergences and lessons to be drawn.Treating paediatric community-acquired pneumonia in the era of antimicrobial resistance.Multidrug-resistant bacterial infections after liver transplantation: an ever-growing challenge.Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile.Early optimization of antimicrobial therapy improves clinical outcomes of patients administered agents targeting methicillin-resistant Staphylococcus aureus.Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy.Update on the management of antibiotic allergyDRESS Syndrome Caused by Cross-reactivity Between Vancomycin and Subsequent Teicoplanin Administration: A Case Report.Optimal teicoplanin dosage regimens for methicillin-resistant Staphylococcus aureus infections in endocarditis patients and renal failure patients.Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction.Change of teicoplanin loading dose requirement for incremental increases of systemic inflammatory response syndrome score in the setting of sepsis.Effect of teicoplanin on Staphylococcus aureus with heterointermediate susceptibility to glycopeptides in experimental infective endocarditis model.Loading regimen required to rapidly achieve therapeutic trough plasma concentration of teicoplanin and evaluation of clinical featuresCefazolin use in patients who report a non-IgE mediated penicillin allergy: a retrospective look at adverse reactions in arthroplasty.Comparison of teicoplanin disk diffusion and broth microdilution methods against clinical isolates of Staphylococcus aureus and S. epidermidis.In vitro evaluation of antibiotics for methicillin-resistant Staphylococcus aureus from north India.Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design
P2860
Q30370676-1B00D9E9-CC86-48CF-A914-E479C6A7E1D7Q31144203-397B1052-399D-420D-840E-63BFD644FC87Q33396270-DAEAB9A5-F8B7-4385-9270-AC0B36C5FB10Q33397749-24E90E15-A3FE-41D9-A517-9568C91A4B63Q33429168-0401031F-8743-4824-A0AC-FCF638153A0EQ35014842-7325EC62-47ED-478E-BDC2-DDF1B0293F22Q35033597-B7D6BEB9-8134-4C53-9184-92C413904E5CQ35105793-61E53E6E-A9F9-420D-A343-7E164542358EQ35598435-9CD05E1B-6D61-4125-8DC7-2BEF66F0940AQ35940556-5E7C7C7E-A14F-458E-B88A-A941795010ADQ36181397-3CFE5B6E-41A4-43F7-A7CF-9618321E25A7Q36243693-F51F0863-202E-4C6D-9713-FFFACE432D0FQ36290681-39200569-1D6F-4B0D-904E-F3A3520BC60FQ36363261-537017AE-7AEC-4DEE-A274-C0123C623607Q36871505-0B5BE571-4E1F-4BDE-B31A-9B8D8CC4F07DQ37287927-EDAB71D7-B2CB-407C-9839-A67DE6630CC5Q37544314-E002CA49-9A8E-459D-94FE-756D3E5A2AD9Q37673485-BF2BE3A4-4799-470E-9E14-247271CC80D7Q37673498-3BD580A9-F461-4CF6-BAEE-04E667ADF1B2Q37956597-90E54418-FEF9-4E4E-993F-D4140CF556F7Q38022551-231E41C2-551E-4F72-8558-43B4FC17F85FQ38052855-3DDAACF0-9B29-4D7A-8272-C1A6C8EDC1AFQ38068293-8C9DED86-D60C-4B9B-AA51-504EE5E28942Q38089918-37DEE72F-1737-4571-A9F7-B9ECB8221184Q38170557-ECBD5504-9BCD-4F24-B11B-6017A4627B6AQ38216011-5B2E797C-4D74-45E1-9D7D-0176A751B421Q38545589-8F0A6F36-B6EE-4257-8C36-84FA13C7AD98Q38672248-93E870F1-C72A-4F1D-9A60-0A5B8BD55A42Q39471413-982BC816-EADF-402C-8E76-95E39C4A9AAAQ39830842-C4887E1E-95A5-42E6-AC80-AC86A785B02DQ40090987-C98D954E-B216-485D-A5F8-629D60C51B14Q40183072-FF9ABF1C-8B4E-4460-8F78-45F3426DF07BQ40640086-237338B1-3892-459E-BA19-EE28737E8CC3Q40695076-1C0469E6-4F65-48AD-A232-2DB4F80CA098Q41229114-53F55D3C-6A08-45DF-858D-9BE4B09D744AQ42089497-0DF59FD7-B435-40B7-930B-CCBF6D206D5FQ42097346-7522C5D5-21FA-4A3C-9E53-984137DC586CQ42181261-BAF60F7D-8679-4AFD-A930-91A604CE1C65Q42539833-13D5BAC1-1F2A-4183-8386-1405F5E7CD73Q42544277-3D79286A-CA2F-4521-A259-61BC615AA05F
P2860
Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Comparative efficacy and safet ...... atic review and meta-analysis.
@en
Comparative efficacy and safet ...... atic review and meta-analysis.
@nl
type
label
Comparative efficacy and safet ...... atic review and meta-analysis.
@en
Comparative efficacy and safet ...... atic review and meta-analysis.
@nl
prefLabel
Comparative efficacy and safet ...... atic review and meta-analysis.
@en
Comparative efficacy and safet ...... atic review and meta-analysis.
@nl
P2860
P356
P1476
Comparative efficacy and safet ...... atic review and meta-analysis.
@en
P2093
Shuli Svetitsky
P2860
P304
P356
10.1128/AAC.00341-09
P407
P577
2009-07-13T00:00:00Z